ATM Gene Mutation

13 registered clinical trials studyying ATM Gene Mutation — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion NCT06033092	European Institute of Oncology	Phase 2
Recruiting	Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors NCT06177171	Pamela Munster	Phase 1
Recruiting	Combination Therapy in Cancers With Mutations in DNA Repair Genes NCT05694715	University of California, San Francisco	Phase 1
Recruiting	An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk a NCT05420064	Memorial Sloan Kettering Cancer Center	N/A
Active Not Recruiting	Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response NCT04030559	Marc Dall'Era, MD	Phase 2
Recruiting	Prostate Cancer Genetic Risk Evaluation and Screening Study NCT05129605	Massachusetts General Hospital	—
Withdrawn	Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer NCT03432676	M.D. Anderson Cancer Center	Phase 2
Completed	Effects of Vitamin B3 in Patients With Ataxia Telangiectasia NCT03962114	Radboud University Medical Center	Phase 2
Terminated	Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Pros NCT03442556	University of Washington	Phase 2
Active Not Recruiting	Olaparib In Metastatic Breast Cancer NCT03344965	Beth Israel Deaconess Medical Center	Phase 2
Completed	Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer NCT03377556	SWOG Cancer Research Network	Phase 2
Recruiting	The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation. NCT05097274	Institute of Cancer Research, United Kingdom	—
Active Not Recruiting	Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations i NCT02286687	M.D. Anderson Cancer Center	Phase 2